Gout

Adolescent gout rates are rising globally, highlighting the need for early intervention and lifestyle changes to mitigate health risks.

A new study utilizing machine learning reveals how physical activity reduces gout risk in people with hyperuricemia.

A recent study reveals a significant prevalence of gout in end-stage renal disease patients, highlighting the complex relationship between kidney function and uric acid levels.

Pegloticase treatment significantly improves serum urate levels and quality of life in kidney transplant recipients with gout, showing promising clinical benefits.

Febuxostat was associated with a nearly 3-fold higher risk of mild to moderate perturbation of liver function than benzbromarone.

Significant associations were seen in males, Mexican Americans, married individuals, those with insufficient physical activity, and those with diabetes.

Dual-energy computed tomography results in faster dissolution of both the core and crown of tophi.

Despite common practice avoiding benzbromarone, new data suggest it has a relatively low hepatotoxicity versus its more common counterpart in gout.

By 3 months, nearly all patients confirmed exposed to 30 or 60 mg SAP-001 reached serum uric acid levels below 6mg/dL.

Other risk factors in the population included PZA or ETB use, hypertension, heart failure, and chronic kidney disease.

MCP-1 and OPN combined had an AUC of 0.938 in diagnosing early renal injury.

XORTX is meeting with the FDA in a Type B meeting regarding a potential NDA for XORLO.

Investigators hope that the model may serve as a foundation for future applications in gout diagnosis.

Dual-energy computed tomography is able to characterize MSU in joints as well as chronic asymptomatic urolithiasis in kidneys.

Levels of the neutrophil activation marker calprotectin correlated with NLR and MLR correlated with total number of gout attacks.

New research highlights the importance of immunomodulation before pegloticase exposure.

A post-hoc analysis evaluated pooled data from 4 trials of pegloticase.

Heat therapy often worsened symptoms in a randomized controlled trial.

However, gout flare states of patient acceptable symptom state, low disease activity, or not achieving either were not associated with EQ-5D-3L or HAQ.

Less than half of rheumatologists self-reported adhering to febuxostat and allopurinol dosing recommendations.

The exploratory MIRROR trial found pegloticase with methotrexate improved clinical assessment and quality of life outcomes in uncontrolled gout.

A study found the association between sedentary behavior and gout remained strong even when adjusting for physical activity.

These findings, from an observational study, should be confirmed in a randomized, controlled trial.

Troum discussed the AGILE study and how DECT scanning helped visualize improvements in uncontrolled gout.

At the highest dose levels, mean plasma urate levels remained below 6.0 mg/dL for up to 12 weeks.